Daiichi Sankyo Announced The Launch Of Ezharmia (Valemetostat Tosilate), A First-In-Class Dual Inhibitor Of Ezh1 And Ezh2, In Japan For The Treatment Of Patients With Relapsed Or Refractory Adult T-Cell Leukaemia-Lymphoma (Atll).Marketing Approval Of Ezharmia Was Granted By Japan
